News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
25,711 Results
Type
Article (3825)
Company Profile (4)
Press Release (21882)
Multimedia
Podcasts (24)
Webinars (4)
Section
Business (8777)
Career Advice (39)
Deals (1236)
Drug Delivery (19)
Drug Development (4398)
Employer Resources (12)
FDA (721)
Job Trends (1075)
News (14850)
Policy (1556)
Tag
Academia (81)
Accelerated approval (1)
Adcomms (2)
Allergies (1)
Alliances (2273)
ALS (2)
Alzheimer's disease (38)
Antibody-drug conjugate (ADC) (75)
Approvals (722)
Artificial intelligence (22)
Autoimmune disease (6)
Automation (2)
Bankruptcy (9)
Best Places to Work (846)
BIOSECURE Act (7)
Biosimilars (6)
Biotechnology (1)
Bladder cancer (17)
Brain cancer (11)
Breast cancer (65)
Cancer (448)
Cardiovascular disease (33)
Career advice (40)
Career pathing (2)
CAR-T (10)
CDC (11)
Cell therapy (20)
Cervical cancer (6)
Clinical research (3737)
Collaboration (76)
Company closure (1)
Compensation (7)
Complete response letters (7)
COVID-19 (205)
CRISPR (2)
C-suite (64)
Cystic fibrosis (2)
Data (208)
Depression (4)
Diabetes (6)
Diagnostics (92)
Diversity, equity & inclusion (3)
Drug discovery (13)
Drug pricing (47)
Drug shortages (1)
Duchenne muscular dystrophy (6)
Earnings (2258)
Editorial (8)
Employer branding (6)
Employer resources (12)
Events (2465)
Executive appointments (82)
FDA (804)
Funding (46)
Gene editing (8)
Generative AI (3)
Gene therapy (16)
GLP-1 (79)
Government (324)
Grass and pollen (1)
Guidances (8)
Healthcare (482)
HIV (9)
Huntington's disease (2)
IgA nephropathy (3)
Immunology and inflammation (23)
Immuno-oncology (11)
Indications (5)
Infectious disease (229)
Inflammatory bowel disease (8)
Inflation Reduction Act (4)
Influenza (1)
Intellectual property (7)
Interviews (2)
IPO (371)
IRA (12)
Job creations (284)
Job search strategy (38)
JPM (8)
Kidney cancer (4)
Labor market (11)
Layoffs (63)
Legal (402)
Liver cancer (7)
Longevity (1)
Lung cancer (107)
Lymphoma (10)
Machine learning (2)
Management (4)
Manufacturing (45)
MASH (6)
Medical device (83)
Medtech (83)
Mergers & acquisitions (901)
Metabolic disorders (43)
Multiple sclerosis (14)
Neurodegenerative disease (15)
Neuropsychiatric disorders (5)
Neuroscience (79)
NextGen: Class of 2026 (199)
Non-profit (91)
Obesity (28)
Opinion (37)
Ovarian cancer (15)
Pain (6)
Pancreatic cancer (5)
Parkinson's disease (4)
Patents (18)
Patient recruitment (7)
People (3910)
Pharmaceutical (2)
Pharmacy benefit managers (3)
Phase I (1077)
Phase II (1676)
Phase III (1560)
Pipeline (181)
Policy (57)
Postmarket research (201)
Preclinical (275)
Press Release (2)
Prostate cancer (6)
Psychedelics (7)
Radiopharmaceuticals (17)
Rare diseases (23)
Real estate (213)
Recruiting (4)
Regulatory (1052)
Reports (7)
Research institute (72)
Resumes & cover letters (1)
RNA editing (1)
RSV (13)
Schizophrenia (4)
Series A (13)
Series B (7)
Sickle cell disease (3)
Special edition (6)
Spinal muscular atrophy (4)
Sponsored (2)
Startups (212)
Stomach cancer (9)
Supply chain (7)
Tariffs (22)
The Weekly (22)
Vaccines (148)
Venture capital (12)
Weight loss (26)
Women's health (2)
Worklife (1)
Date
Today (1)
Last 7 days (22)
Last 30 days (88)
Last 365 days (1024)
2026 (88)
2025 (1024)
2024 (1236)
2023 (1319)
2022 (2976)
2021 (2787)
2020 (2293)
2019 (1546)
2018 (1196)
2017 (1348)
2016 (1159)
2015 (1327)
2014 (867)
2013 (725)
2012 (785)
2011 (880)
2010 (816)
Location
Africa (65)
Alabama (4)
Alaska (1)
Arizona (2)
Asia (1565)
Australia (399)
California (194)
Canada (82)
China (88)
Colorado (5)
Connecticut (7)
Delaware (14)
Europe (4365)
Florida (59)
Georgia (2)
Illinois (11)
Indiana (2)
Japan (56)
Kansas (1)
Kentucky (1)
Maryland (46)
Massachusetts (236)
Michigan (1)
Minnesota (2)
Mississippi (1)
Missouri (3)
Nevada (1)
New Hampshire (4)
New Jersey (264)
New York (83)
North Carolina (18)
Northern California (103)
Ohio (3)
Oregon (1)
Pennsylvania (25)
Rhode Island (4)
South America (61)
Southern California (66)
Tennessee (1)
Texas (26)
United States (1010)
Utah (8)
Virginia (7)
Washington D.C. (5)
Washington State (27)
West Virginia (1)
Wisconsin (1)
25,711 Results for "merck kgaa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
aptaTargets transferred ApTOLL to Merck KGaA, Darmstadt, Germany
ApTOLL completed a Phase 1b/2 clinical trial for acute ischemic stroke with positive results. Merck KGaA, Darmstadt, Germany, to assume clinical development and commercialization of ApTOLL.
May 22, 2025
·
1 min read
Mergers & acquisitions
Merck KGaA Moves Ahead on SpringWorks Buy for $3.9B
The transaction is expected to close in the second half of 2025. With the deal, Merck KGaA is adding to its rare disease and oncology pipelines.
April 28, 2025
·
3 min read
·
Tristan Manalac
Press Releases
Flex and Merck KGaA, Darmstadt, Germany, Win 2025 PDA Drug Delivery Innovation Award
November 14, 2025
·
2 min read
Mergers & acquisitions
Merck KGaA Courts Cancer Biotech SpringWorks for Potential Buyout
Following an initial report from
Reuters
, Merck KGaA confirmed that it is in talks with SpringWorks for a potential acquisition, though details of its offer have yet to be revealed.
February 11, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Valo Health Announces Collaboration with Merck KGaA, Darmstadt, Germany to Discover and Develop Novel Treatments for Parkinson’s Disease and Related Disorders
November 21, 2025
·
3 min read
Mergers & acquisitions
Merck Backs Off Revolution After Failing To Agree on Price: WSJ
Merck had previously offered anywhere from $28 billion to $32 billion to swallow Revolution Medicines.
January 26, 2026
·
1 min read
·
Tristan Manalac
Mergers & acquisitions
Revolution Knows Its Worth as Merck Backs Off—For Now
Investors are apparently taking bets on when Revolution will be acquired. A handful of pharmas could be interested as Merck backs off.
January 26, 2026
·
4 min read
·
Annalee Armstrong
Ovarian cancer
Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities said Thursday.
January 26, 2026
·
2 min read
·
Tristan Manalac
Neuroscience
Merck KGaA Drops up to $2B in Skyhawk Collab for RNA-Targeting Tech
Waltham, Massachusetts–based Skyhawk Therapeutics has been collecting collaborations with larger companies in spades since launching in 2018.
August 18, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
September 4, 2025
·
4 min read
1 of 2,572
Next
